3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
pembrolizumab
39
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Standard of Care
17
Nivolumab
17
Carboplatin
17
Paclitaxel
15
Exercise
15
Gemcitabine
14
atezolizumab
13
Pemetrexed
13
Cisplatin
13
Radiotherapy
11
Fluorouracil
11
Doxorubicin
11
Cetuximab
10
130-nm albumin-bound paclitaxel
10
durvalumab
9
Rituximab
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
Biopsy
9
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Prednisone
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled